Be Biopharma

Executive Summary

Be Biopharma is a clinical-stage biotechnology company pioneering a novel class of engineered B cell medicines (BCMs). Founded in 2020 and based in Cambridge, MA, the company leverages its proprietary platform to create durable, redosable, and controllable cell therapies that produce therapeutic proteins in vivo. Its initial focus is on rare diseases, with a lead program targeting hemophilia B. The B cell platform offers potential advantages over traditional gene therapies, including the ability to re-dose and fine-tune protein expression, which could address key limitations in durability and safety. Be Biopharma is positioned to address significant unmet needs in hemophilia B and expand into other rare protein deficiencies. The company has attracted investor interest due to its differentiated approach, though it remains in the pre-clinical stage without disclosed funding amounts or valuation. The successful advancement of its lead program into clinical trials will be a critical milestone.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Hemophilia B Program60% success
• Q4 2026Presentation of Preclinical Proof-of-Concept Data at Major Conference80% success
• Q2 2027Series B or C Financing Round70% success